Scalp Psoriasis: Beyond Dandruff

Understanding Scalp Psoriasis

Scalp psoriasis occurs in 50-80% of patients with psoriasis, making it the second most common site after the trunk. The scalp presents unique treatment challenges due to hair coverage, sebaceous gland density, and limited penetration of topical therapies. Unlike seborrheic dermatitis or simple dandruff, scalp psoriasis involves infiltration of T-lymphocytes and dendritic cells into the stratum basale, creating characteristic psoriasiform inflammation. The condition often proves more resistant to treatment than plaque psoriasis on smooth skin, requiring combination therapies and systemic management for severe cases. Approximately 15-20% of psoriasis patients experience scalp disease exclusively.

Epidemiology and Prevalence

Scalp psoriasis affects approximately 15-22 million individuals with psoriasis worldwide. The condition occurs at similar rates in males and females, though males tend to experience more severe scalp involvement. Age of onset parallels systemic psoriasis (typically 20-40 years). Approximately 50% of patients with scalp involvement develop it within 1-5 years of initial psoriasis diagnosis. The scalp's constant microtrauma from grooming, hair washing, and scratching perpetuates inflammation—the Koebner phenomenon affects 80-90% of scalp psoriasis patients. Individuals with HLA-C*06:02 positivity (found in 85-90% of early-onset psoriasis) show higher rates of scalp involvement.

Pathophysiology and Scalp-Specific Factors

Scalp psoriasis develops through Th1/Th17-mediated immune activation with IL-17A, IL-23, TNF-alpha, and IFN-gamma accumulating in lesional tissue. The scalp's unique microenvironment—high sebaceous gland density, occlusion from hair, heat retention, increased skin temperature (up to 1-2°C higher than facial skin), and constant microtrauma—promotes psoriasiform inflammation. Malassezia yeasts, normally commensal, proliferate in the sebum-rich environment and secrete lipids that trigger innate immune activation in susceptible individuals. The stratum corneum on the scalp is thicker (200-400 micrometers versus 15-20 micrometers on face), limiting penetration of most topical agents. Chronic microtrauma from scratching causes barrier disruption, further perpetuating inflammation through TLR activation.

Clinical Presentation and Severity

Scalp psoriasis manifests as well-demarcated, erythematous plaques with silvery-white scales, typically initiating at the hairline margin (frontal border), vertex, and occipital region. Plaques may extend beyond hair-bearing skin onto the forehead, ears, and neck. Pruritus occurs in 70-80% of patients, ranging from mild to severe. Scale accumulation creates visible white deposits on dark clothing. In severe cases, diffuse erythema and exudative plaques occur, occasionally progressing to erythroderma if systemic triggers precipitate flares. Associated hair loss (alopecia) affects 5-10% of patients from chronic inflammation and scratching. The condition impacts psychological wellbeing, with 40-50% of patients experiencing embarrassment and social anxiety from visible scaling.

Diagnostic Approach

Diagnosis is clinical, based on characteristic psoriasiform plaques with scales in the scalp. Dermoscopy reveals regular elongation of rete ridges, dilated capillaries in papillary dermis, and thinned suprapapillary epidermis. Scalp biopsy (rarely necessary) confirms psoriasiform inflammation. Differential diagnosis includes seborrheic dermatitis (less well-demarcated, greasy rather than silvery scales, non-pruritic or mildly pruritic, responds to ketoconazole alone), dandruff/pityriasis simplex (minimal inflammation, responds to zinc pyrithione alone), and fungal infection (KOH preparation negative in psoriasis). Careful examination of other body sites for psoriasis plaques supports diagnosis.

Treatment Approaches

Topical therapies form first-line management: potent corticosteroids (clobetasol 0.05% foam, solution, or shampoo applied twice daily) penetrate better than occlusive formulations due to hair parting. Application with occlusion (plastic wrap 4-8 hours weekly or overnight) enhances penetration, achieving 40-50% improvement in 4-6 weeks. Calcipotriol 50 mcg/g solutions applied twice daily benefit 30-40% of patients within 6-8 weeks. Combination therapy (corticosteroid plus calcipotriol) exceeds either monotherapy (55-65% response) and should be applied sequentially to avoid corticosteroid-induced vitamin D receptor antagonism.

Medicated shampoos containing zinc pyrithione (1-2%), selenium sulfide (2.5%), or ketoconazole (1-2%) provide additional benefit when used 3-5 times weekly, though they penetrate poorly to inflamed tissue. These agents reduce associated dermatophytes and Malassezia, helping normalize scalp microbiota. Salicylic acid shampoos (1-3%) help remove scale buildup but may irritate when scalp is severely inflamed.

Systemic therapies address moderate-to-severe scalp disease: methotrexate (10-25 mg weekly) benefits 60-75% of patients with visible improvement at 8-12 weeks. Acitretin (0.5-1 mg/kg/day) shows efficacy in 50-60% of cases, particularly for scalp plaques. TNF-inhibitors (etanercept 50 mg weekly, infliximab 5 mg/kg at 0,2,6 weeks then every 8 weeks, adalimumab 40 mg every 2 weeks) achieve response in 70-85% with improvement visible at 4-8 weeks. IL-17 inhibitors (secukinumab 150 mg weekly for 4 weeks, then monthly) and IL-23 inhibitors (risankizumab 150 mg IV) show superior efficacy (75-90% response) in scalp disease specifically, with faster onset than TNF inhibitors.

Long-term Management

Continuous maintenance therapy prevents relapse; 60-70% of patients flare within 3-6 months of stopping effective systemic treatment. Regular shampooing with mild cleansers, avoiding harsh scrubbing, and moisture management benefit disease control. Reduction of emotional stress, a major trigger for 40-50% of patients, through counseling and stress management improves outcomes. Avoidance of traumatic hair procedures (excessive blow-drying, tight hairstyles) prevents Koebner flares in susceptible patients.

Frequently Asked Questions

Does scalp psoriasis cause hair loss?

Scalp psoriasis rarely causes permanent hair loss, though temporary shedding occurs due to inflammation and scale disruption. Approximately 25-35% of patients experience reversible alopecia during active disease. Hair regrows within 3-6 months of achieving scalp clearance. Persistent scratching increases mechanical hair loss. Aggressive treatment resolves both psoriasis and associated hair shedding.

Is scalp psoriasis contagious?

No — scalp psoriasis is an autoimmune condition, not infectious. It cannot spread through contact, shared combs, brushes, or hats. Sharing personal grooming items poses no transmission risk. The condition reflects individual immune dysregulation and genetic predisposition. Poor hygiene does not cause it, and cleanliness does not prevent it.

What OTC treatments work for scalp psoriasis?

First-line OTC agents include zinc pyrithione (1-2%) and salicylic acid (1-3%) shampoos. Ketoconazole 1% is available OTC. Topical corticosteroids (hydrocortisone 1%) are weak but safe OTC options. Scalp lotions with coal tar or sulfur (2-5%) are also available. OTC agents help mild cases; moderate-to-severe disease requires prescription-strength corticosteroid solutions or foams.

Which is better: coal tar or salicylic acid?

Both are effective but work differently. Coal tar reduces inflammation and scales; salicylic acid dissolves plaques and removes scale. Many products combine both. Coal tar is stronger for thick plaques but causes staining and odor. Salicylic acid is gentler and less messy. Efficacy is similar (60-70% improvement); choice depends on tolerance and preference. Rotation prevents resistance.

Can I color my hair with scalp psoriasis?

Hair coloring is safe once active psoriasis is controlled. Active plaques increase scalp sensitivity to chemical irritation and increase flare risk. If coloring during active disease, use gentle semi-permanent dyes and patch-test first. Avoid coloring during treatment with corticosteroids; wait 1-2 weeks post-treatment. Once clear, normal coloring resumes without increased risk.

How do I prevent scalp psoriasis from spreading to my face?

Scalp psoriasis can spread to hairline, ears, and face (seborrheic distribution). Keep nails short to prevent traumatic spread. Use designated towels and avoid touching lesions. Treat scalp disease aggressively to prevent spread. Once facial involvement occurs, add gentle facial corticosteroids or calcineurin inhibitors. Scalp disease control reduces facial involvement risk by 40-50%.

References